Compare THM & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THM | JANX |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.2M | 790.3M |
| IPO Year | 2002 | 2021 |
| Metric | THM | JANX |
|---|---|---|
| Price | $2.57 | $13.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $53.60 |
| AVG Volume (30 Days) | ★ 1.6M | 784.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $209.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.46 | $12.12 |
| 52 Week High | $3.65 | $35.34 |
| Indicator | THM | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 46.12 |
| Support Level | $2.17 | $13.01 |
| Resistance Level | $3.63 | $13.79 |
| Average True Range (ATR) | 0.28 | 0.55 |
| MACD | -0.08 | 0.07 |
| Stochastic Oscillator | 3.13 | 37.58 |
International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project namely the Livengood Gold Project. It is located in northwest of Fairbanks, Alaska in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.